CalciMedica Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

CalciMedica is a clinical-stage biotechnology company focused on developing therapies that inhibit calcium release-activated calcium (CRAC) channels to modulate immune responses and reduce tissue injury in serious inflammatory and immunologic diseases. By targeting CRAC channels, the company aims to address conditions with few approved treatment options. Its lead candidate, Auxora, has shown positive efficacy signals across completed trials and has been well tolerated in more than 350 critically ill patients dosed. The firm is advancing a Phase 2 program in acute pancreatitis with systemic inflammatory response syndrome (CARPO) and a Phase 2 study in COVID pneumonia (CARDEA), as well as a Phase 2 trial in acute kidney injury with associated acute hypoxemic respiratory failure (KOURAGE).
Headquartered in La Jolla, California, CalciMedica operates as a smaller biotechnology research enterprise. In June 2026, the U.S. FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial and allowed continued development of Auxora across its indications.

Get verified CalciMedica emails free

Company overview Employee directory